Akari Therapeutics: Interim CFO Wendy DiCicco departs; CEO Samir Patel assumes interim PFO/PAO roles

Akari Therapeutics Plc

Wendy DiCicco's consulting agreement terminated on December 6, 2024, ending her role as Interim CFO, PFO, and PAO.
Samir Patel, Interim CEO, appointed as Interim Principal Financial Officer and Principal Accounting Officer effective December 12, 2024.
Board initiated search for a new Chief Financial Officer.
Separation terms for DiCicco are being finalized and will be disclosed in a subsequent filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.